Gut Microbiota Dysbiosis Drives Resistance Gene Transfer and Bacterial Adaptation
DOI:
https://doi.org/10.21070/ijhsm.v2i1.163Keywords:
Gut Microbiota, Antimicrobial Resistance, Dysbiosis, Probiotics, Therapeutic StrategiesAbstract
Antimicrobial resistance (AMR) has emerged as a global health crisis, threatening the efficacy of modern medicine. The gut microbiota, a densely populated microbial ecosystem, plays a critical role in modulating host immunity, metabolism, and resistance to pathogen colonization. Disruption of this microbial balance—gut dysbiosis—creates an environment conducive to the proliferation and horizontal transfer of antibiotic resistance genes (ARGs), contributing to the development of multidrug-resistant organisms (MDROs). This review explores the molecular and ecological mechanisms through which gut dysbiosis influences AMR and examines therapeutic approaches aimed at restoring microbial homeostasis to combat this pressing challenge. Antimicrobial resistance (AMR) is a pressing global health concern, and recent studies have revealed the human gut microbiota as a significant reservoir of resistance genes. Dysbiosis—an imbalance in the composition and function of gut microbiota—can enhance the persistence and transfer of antibiotic resistance genes (ARGs) among microbial populations. This review explores the mechanisms linking gut dysbiosis to AMR, highlights recent findings on microbial-host interactions, and discusses emerging therapeutic strategies such as probiotics, fecal microbiota transplantation (FMT), and microbiota-modulating diets to combat resistance development. Understanding these dynamics is critical for advancing personalized medicine and curbing the spread of drug-resistant infections.
Highlights:
- Dysbiosis Promotes AMR – Gut imbalance helps antibiotic resistance genes spread.
- Gut as ARG Reservoir – The gut hosts many resistance genes that can transfer between microbes.
- Therapies Target Microbiota – Probiotics, FMT, and diets may restore balance and fight AMR.
Keywords: Gut Microbiota, Antimicrobial Resistance, Dysbiosis, Probiotics, Therapeutic Strategies
References
[1] Pamer, E. G., "Resurrecting the Intestinal Microbiota to Combat Antibiotic-Resistant Pathogens," Science, vol. 352, no. 6285, pp. 535–538, 2016.
[2] Van Schaik, W., "The Human Gut Resistome," Philosophical Transactions of the Royal Society B, vol. 370, no. 1670, 20140087, 2015.
[3] Becattini, S., Taur, Y., and Pamer, E. G., "Antibiotic-Induced Changes in the Intestinal Microbiota and Disease," Trends in Molecular Medicine, vol. 22, no. 6, pp. 458–478, 2016.
[4] Huang, H., Jiang, J., Wang, X., Jiang, K., and Cao, H., "Exposure to Prescribed Medication in Early Life and Impacts on Gut Microbiota and Disease Development," eClinicalMedicine, vol. 68, 102428, 2024.
[5] Forslund, K., et al., "Resistome Expansion in Disease-Associated Human Gut Microbiomes," Microbiome, vol. 11, p. 166, 2023.
[6] The American Society for Microbiology, "The Gut Resistome and the Spread of Antimicrobial Resistance," 2022. [Online]. Available: https://asm.org/articles/2022/june/the-gut-resistome-and-the-spread-of-antimicrobial
[7] Health.com, "Steps You Can Take for Improved Gut Health," 2023. [Online]. Available: https://www.health.com/how-to-improve-gut-health-7507574
[8] PubMed, "The Impact of Antibiotic Therapy on Intestinal Microbiota: Dysbiosis, Antibiotic Resistance, and Restoration Strategies," 2023. [Online]. Available: https://pubmed.ncbi.nlm.nih.gov/40298495/
[9] Frontiers in Immunology, "Harnessing the Human Gut Microbiota: An Emerging Frontier in Combatting Multidrug-Resistant Bacteria," 2025. [Online]. Available: https://www.frontiersin.org/articles/10.3389/fimmu.2025.1563450/full
[10] Sekirov, I., Russell, S. L., Antunes, L. C., and Finlay, B. B., "Gut Microbiota in Health and Disease," Physiol Rev., vol. 90, no. 3, pp. 859–904, 2010.
[11] Koh, A., et al., "From Dietary Fiber to Host Physiology: Short-Chain Fatty Acids as Key Bacterial Metabolites," Cell, vol. 165, no. 6, pp. 1332–1345, 2016.
[12] Wilson, I. D. and Nicholson, J. K., "Gut Microbiome Interactions with Drug Metabolism, Efficacy, and Toxicity," Transl Res., vol. 179, pp. 204–222, 2017.
[13] Gopalakrishna, K. P., et al., "Maternal IgA Protects Against the Development of Necrotizing Enterocolitis in Preterm Infants," Nat Med., vol. 25, pp. 1110–1115, 2019.
[14] Selma-Royo, M., et al., "Perinatal Environment Shapes Microbiota Colonization and Infant Growth: Impact on Host Response and Intestinal Function," Microbiome, vol. 8, p. 167, 2020.
[15] Dawson-Hahn, E. E. and Rhee, K. E., "The Association Between Antibiotics in the First Year of Life and Child Growth Trajectory," BMC Pediatr., vol. 19, p. 23, 2019.
[16] Persaud, R. R., et al., "Perinatal Antibiotic Exposure of Neonates in Canada and Associated Risk Factors: A Population-Based Study," J Matern Fetal Neonatal Med., vol. 28, pp. 1190–1195, 2015.
[17] Leong, K. S. W., et al., "Associations of Prenatal and Childhood Antibiotic Exposure With Obesity at Age 4 Years," JAMA Netw Open, vol. 3, e1919681, 2020.
[18] Slykerman, R. F., et al., "Antibiotics in the First Year of Life and Subsequent Neurocognitive Outcomes," Acta Paediatr., vol. 106, pp. 87–94, 2017.
[19] Y. Noh, E.-S. Kwon, J. Choi, Y. S. Choe, M. Kim, and H.-J. Yang, “Prenatal and Infant Exposure to Acid-Suppressive Medications and Risk of Allergic Diseases in Children,” JAMA Pediatr., vol. 177, no. 2, pp. 146–154, Feb. 2023, doi: 10.1001/jamapediatrics.2022.5193.
[20] T. W. Sadler, M. W. Gillman, M. M. Dotterer, M. L. Glymour, and N. E. Adler, “Air Pollution and Neurodevelopmental Outcomes: A Review of the Current Literature and Public Health Implications,” JAMA Pediatrics, vol. 177, no. 3, pp. 267–277, Mar. 2023, doi: 10.1001/jamapediatrics.2022.5946.
[21] Neuman, H., et al., "Antibiotics in Early Life: Dysbiosis and the Damage Done," FEMS Microbiol Rev., vol. 42, pp. 489–499, 2018.
[22] Y. Zhou, C. Qiu, Y. Jin, Z. Yang, and Y. Luo, “Intrauterine Antibiotic Exposure Affected Neonatal Gut Bacteria and Infant Growth Speed,” Environmental Pollution, vol. 289, p. 117901, Nov. 2021, doi: 10.1016/j.envpol.2021.117901.
[23] L. Chen, Y. Yang, X. Jiang, Y. Xing, and Y. Chen, “Association Between Particulate Air Pollution and Risk of Depression in China: A Population-Based Study,” Environmental Pollution, vol. 289, p. 117901, Jan. 2021, doi: 10.1016/j.envpol.2021.117901.
[24] Hutchings, M. I., Truman, A. W., and Wilkinson, B., "Antibiotics: Past, Present and Future," Curr Opin Microbiol, vol. 51, pp. 72–80, 2019.
[25] Antimicrobial Resistance Collaborators, "Global Burden of Bacterial Antimicrobial Resistance in 2019: A Systematic Analysis," Lancet, vol. 399, pp. 629–655, 2022.
[26] Young, V. B., "The Role of the Microbiome in Human Health and Disease: An Introduction for Clinicians," BMJ, vol. 356, j831, 2017.
[27] Li, J., et al., "Interplay Between Diet and Gut Microbiome, and Circulating Concentrations of Trimethylamine N-Oxide," Gut, vol. 71, pp. 724–733, 2022.
[28] Stiemsma, L. T. and Michels, K. B., "The Role of the Microbiome in the Developmental Origins of Health and Disease," Pediatrics, vol. 141, e20172437, 2018.
[29] Guo, J., et al., "Gut Dysbiosis During Early Life: Causes, Health Outcomes, and Amelioration via Dietary Intervention," Crit Rev Food Sci Nutr., vol. 62, pp. 7199–7221, 2022.
[30] Schnizlein, M. K. and Young, V. B., "Capturing the Environment of the Clostridioides difficile Infection Cycle," Nat Rev Gastroenterol Hepatol, vol. 19, pp. 508–520, 2022.
[31] Willems, R. P. J., et al., "Incidence of Infection With Multidrug-Resistant Gram-Negative Bacteria and Vancomycin-Resistant Enterococci in Carriers," Lancet Infect Dis., vol. 23, pp. 719–731, 2023.
[32] Dubinsky-Pertzov, B., et al., "Carriage of Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae and the Risk of Surgical Site Infection," Clin Infect Dis., vol. 68, pp. 1699–1704, 2019.
[33] Ianiro, G., et al., "Incidence of Bloodstream Infections and Survival in Patients With Recurrent Clostridioides difficile Treated With FMT or Antibiotics," Ann Intern Med., vol. 171, pp. 695–702, 2019.
[34] Pérez-Nadales, E., et al., "Prognostic Significance of KPC-Producing Klebsiella pneumoniae in Intestinal Microbiota," Microbiol Spectr., vol. 10, e0272821, 2022.
[35] Rao, K., et al., "Enterobacterales Infection After Intestinal Dominance in Hospitalized Patients," mSphere, vol. 5, e00450-20, 2020.
[36] Lee, N. C., Larionov, V., and Kouprina, N., "Highly Efficient CRISPR/Cas9-Mediated TAR Cloning in Yeast," Nucl Acids Res., vol. 43, 2015.
[37] Feng, Z., et al., "Efficient Genome Editing in Plants Using a CRISPR/Cas System," Cell Res., vol. 23, pp. 1229–1232, 2013.
[38] Jiang, W., et al., "CRISPR/Cas9-Mediated Gene Modification in Plants," Nucl Acids Res., vol. 41, 2013.
[39] Kim, H., et al., "A Co-CRISPR Strategy for Efficient Genome Editing in Caenorhabditis Elegans," Genetics, vol. 197, pp. 1069–1080, 2014.
[40] Bassett, A. R., et al., "Targeted Mutagenesis of Drosophila With the CRISPR/Cas9 System," Cell Rep., vol. 4, pp. 220–228, 2013.
[41] Hwang, W. Y., et al., "Efficient Genome Editing in Zebrafish Using a CRISPR-Cas System," Nat Biotechnol., vol. 31, pp. 227–229, 2013.
[42] Guo, X., et al., "RNA/Cas9-Mediated Genome Editing in Xenopus tropicalis," Development, vol. 141, pp. 707–714, 2014.
[43] Wu, Y., et al., "Correction of a Genetic Disease in Mouse Using CRISPR-Cas9," Cell Stem Cell, vol. 13, pp. 659–662, 2013.
[44] Ma, Y., et al., "Generating Rats With Conditional Alleles Using CRISPR/Cas9," Cell Res., vol. 24, pp. 122–125, 2014.
[45] Song, Y., et al., "CRISPR/Cas9 Deletion of Glucokinase in Rabbit Leads to Hyperglycemia," Cell Mol Life Sci., vol. 77, pp. 3265–3277, 2020.
[46] Zou, Q., et al., "Generation of Gene-Target Dogs Using CRISPR/Cas9," J Mol Cell Biol., vol. 7, pp. 580–583, 2015.
[47] Ma, T., et al., "Melatonin-Enriched Milk via CRISPR/Cas9-Engineered Sheep," J Pineal Res., vol. 63, 2017.
[48] Niu, D., et al., "Inactivation of Porcine Endogenous Retrovirus in Pigs Using CRISPR-Cas9," Science, vol. 357, pp. 1303–1307, 2017.
[49] Niu, Y. Y., et al., "Generation of Gene-Modified Cynomolgus Monkey via Cas9/RNA," Cell, vol. 156, pp. 836–843, 2014.
[50] Xiong, X., et al., "CRISPR/Cas9 for Human Genome Engineering and Disease Research," Annu Rev Genomics Hum Genet., vol. 17, pp. 131–154, 2016.
[51] Zarei, A., et al., "Creating Cell and Animal Models of Human Disease by Genome Editing Using CRISPR/Cas9," J Gene Med., vol. 21, 2019.
[52] Rodríguez-Rodríguez, D. R., et al., "Application of CRISPR/Cas9 to Study Human Diseases," Int J Mol Med., vol. 43, pp. 1559–1574, 2019.
[53] Rydell-Törmänen, K. and Johnson, J. R., "Applicability of Mouse Models to Study Human Disease," Methods Mol Biol., vol. 1940, pp. 3–22, 2019.
[54] Platt, R. J., et al., "CRISPR-Cas9 Knockin Mice for Genome Editing and Cancer Modeling," Cell, vol. 159, pp. 440–455, 2014.
[55] Yang, S., et al., "CRISPR/Cas9-Mediated Gene Editing Ameliorates Neurotoxicity in Huntington's Disease," J Clin Invest., vol. 127, pp. 2719–2724, 2017.
[56] Li, P., et al., "Myo3a Y137C Knock-In Mice Display Hearing Loss and Hair Cell Degeneration," Neural Plast., vol. 2018, p. 4372913, 2018.
[57] Wang, L., et al., "CRISPR/Cas9-Mediated Gene Targeting Corrects Hemostasis in Factor IX-Knockout Mice," Blood, vol. 133, pp. 2745–2752, 2019.
[58] Matharu, N., et al., "CRISPR Activation of Promoter/Enhancer Rescues Obesity From Haploinsufficiency," Science, vol. 363, 2019.
[59] Yang, Y., et al., "Dual AAV Enables Cas9-Mediated Correction of Liver Disease in Newborn Mice," Nat Biotechnol., vol. 34, pp. 334–338, 2016.
[60] Li, X. J. and Li, W., "Genetically Modifying Larger Animals to Model Human Diseases," J Genet Genomics, vol. 39, pp. 237–238, 2012.
[61] Yuan, L., et al., "CRISPR/Cas9-Mediated GJA8 Knockout Causes Cataracts in Rabbits," Sci Rep., vol. 6, p. 22024, 2016.
[62] Yuan, L., et al., "Mutation of αA-Crystallin Gene Induces Cataracts in Rabbits," Invest Ophthalmol Vis Sci., vol. 58, pp. BIO34–BIO41, 2017.
[63] Lv, Q., et al., "D-Repeat in the XIST Gene is Required for X Chromosome Inactivation," RNA Biol., vol. 13, pp. 172–176, 2016.
[64] Song, Y., et al., "Mutation of Sp1 Binding Site in SRY Causes Sex Reversal in Rabbits," Oncotarget, vol. 8, pp. 38176–38183, 2017.
[65] Song, Y., et al., "CRISPR/Cas9 Mutation of Tyr 3' UTR Induces Graying in Rabbit," Sci Rep., vol. 7, p. 1569, 2017.
[66] Xu, Y., et al., "Phenotype Identification of PAX4 Knockout Rabbit by CRISPR/Cas9," G3 (Bethesda), vol. 8, pp. 2833–2840, 2018.
[67] Chen, M., et al., "Truncated Fibrillin-1 Induces Marfanoid-Progeroid-Lipodystrophy in Rabbit," Dis Model Mech., vol. 11, 2018.
[68] Deng, J., et al., "Hoxc13-Ablated Rabbits Show Balance Disruption in Hair Follicles," FASEB J., vol. 33, pp. 1226–1234, 2019.
[69] Sui, T., et al., "A Novel Rabbit Model of Duchenne Muscular Dystrophy via CRISPR/Cas9," Dis Model Mech., vol. 11, 2018.
[70] Sui, T., et al., "CRISPR Engineered ANO5 Mutation Leads to Muscular Dystrophy in Rabbit," Cell Death Dis., vol. 9, p. 609, 2018.
[71] Sui, T., et al., "LMNA-Mutated Rabbits as a Model of Premature Aging," Aging Dis., vol. 10, pp. 102–115, 2019.
[72] Liu, T., et al., "DMP1 Ablation in Rabbit Results in Bone Microarchitecture Defects," J Bone Miner Res., vol. 34, pp. 1115–1128, 2019.
[73] Lu, Y., et al., "GADD45G Mutation Causes Cleft Lip in Rabbits," Biochim Biophys Acta Mol Basis Dis., vol. 1865, pp. 2356–2367, 2019.
[74] Liu, Z., et al., "Highly Efficient RNA-Guided Base Editing in Rabbit," Nat Commun., vol. 9, p. 2717, 2018.
[75] Liu, H., et al., "Multiple Gene Knockout in Rabbit Using CRISPR/Cas9," Gene, vol. 647, pp. 261–267, 2018.
[76] Yang, H. and Wu, Z., "Genome Editing of Pigs for Agriculture and Biomedicine," Front Genet., vol. 9, p. 360, 2018.
[77] Zhou, X., et al., "Generation of Gene-Targeted Pigs via CRISPR/Cas9 and SCNT," Cell Mol Life Sci., vol. 72, pp. 1175–1184, 2015.
[78] Yan, S., et al., "A Huntingtin Knockin Pig Model Recapitulates Huntington's Disease," Cell, vol. 173, pp. 989–1002, 2018.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Shaymaa Mahmood Ali, Ammar Adnan Tuama
This work is licensed under a Creative Commons Attribution 4.0 International License.
